Vivo Opportunity Fund Holdings, LP

10% owner Vivo Opportunity buys 6,551 shares (6.6K) at $1.54–$1.55 over 3 days for $10,148.05

Vivo Opportunity, LLC (10% owner of InMed Pharmaceuticals) executed 6 separate purchases totaling 6,551 shares for $10,148.05 at blended average price $1.55 between June 30 and July 2, 2026, increasing holdings by 9.8% to 73,135 shares. The current price of $1.56 is nearly identical to the transaction prices, placing the stock 56.1% below its 52-week high of $3.55 and within the recent 90-day rebound of 130.1%. InMed remains unprofitable ($-3.0M net income in the latest full fiscal year) with minimal quarterly revenue ($820.2K), though annual revenue growth stands at 7.5%. Prior trades by Vivo Opportunity at this same ticker (5 buys on 2026-06-04 through 2026-06-08) are too recent to have measurable returns. The cross-ticker track record shows 18 prior buys averaging -2.6% 30-day return, providing limited predictive value for this specific transaction.

10% owner Vivo Opportunity bought 249,227 shares for $391,554.51 across 18 trades (May–June 2026), blended avg $1.57.

Vivo Opportunity, LLC, a 10% shareholder, executed 18 separate purchases totaling 249,227 shares for $391,554.51 between May 20 and June 8, 2026, at prices ranging from $1.52 to $1.69 with a blended average of $1.57. The transaction occurred amid significant stock volatility: the current price of $1.51 is -72.6% from the 52-week high of $5.50, while the stock has gained +143.2% over the past 30 days and +88.8% over 90 days. The company reported a net loss of $-3.0M on quarterly revenue of $820.2K and remains unprofitable on a full-year basis, with a market cap of $5.0M. The fractured purchase pattern (small add-ons paired with larger blocks on each date) and multi-week accumulation at depressed valuations relative to the 52-week range warrant attention as to whether this represents a significant capital commitment by an existing major shareholder or portfolio-level activity.

10% owner Vivo Opportunity LLC sold 1,833,557 shares (1.83M) for $124,449,124.20 across 3 trades (Mar 26–28), blended avg $67.87, reducing stake by 29.1%.

Vivo Opportunity, LLC executed three separate sales totaling 1,833,557 shares for $124,449,124.20 on March 26–28, reducing its stake from 6,291,851 shares to 4,458,294 shares (-29.1%). The blended average price of $67.87 sits below the current price of $71.99, and the stock has risen +59.6% over the past 30 days and +60.6% over 90 days—both periods encompassing recent strong upward momentum. Historically at SLNO, this insider's prior five trades (Aug 28–29 and Apr 29–30, 2024) all posted positive 90-day returns (+0.1% to +23.2%), with 0 of 5 sales being well-timed on a 90-day basis, indicating the stock tended to rise after prior sales. The company reports negative net income of $-76,616,000.00 for the latest period and is unprofitable on a full-year basis, despite annual revenue growth of +138.8%, which may merit scrutiny regarding the rapid recent price appreciation. The sale's magnitude ($124.4M notional value) and the concentration of three trades within 48 hours warrant attention to the insider's repositioning rationale.

10% owner Vivo Opportunity sells 1,025,000 SLNO shares for $49.2M; stock down 11.1% from highs

Vivo Opportunity, LLC, a 10% owner, executed 3 separate sales totaling 1,025,000 shares for $49,210,750.00 on August 27–29, 2024, reducing its stake by 14.0% from 7.32M to 6.29M shares. The blended average sale price was $48.01, achieved near the 52-week high of $52.35; the stock now trades at $46.56, down 11.1% from its peak. At SLNO specifically, this seller's prior 2 trades (April 2024) demonstrated poor 90-day timing (both posted positive returns, meaning the stock rose after the sales). This transaction occurs in a company with minimal recent revenue ($1.0K in the latest quarter) and severe net losses ($-21.9M annually), despite 138.8% annual revenue growth. The scale and timing of this reduction—selling over $49M in value near the stock's high—warrant scrutiny of underlying business fundamentals and the 10% holder's forward outlook.